Philip H. Coelho - 21 May 2021 Form 4 Insider Report for Ampio Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Daniel Stokely, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 21 May 2021
Net transactions value: -$10,779
Form type: 4
Filing time: 25 May 2021, 15:44:16 UTC
Next filing: 26 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMPE	Common Stock	Options Exercise	$2,695	+6,737	+3.3%	$0.4000	210,237	21 May 2021	Direct	F1
transaction	AMPE	Common Stock	Sale	$13,474	-6,737	-3.2%	$2.00^*	203,500	21 May 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMPE	Stock Option (Right to Buy)	Options Exercise	$0	-6,737	-100%	$0.000000^*	0	21 May 2021	Common Stock	6,737	$0.4000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 30, 2021.
F2	Options were granted and previously reported on a Form 4 filed on January 9, 2019, where the stock option vested and became exercisable in 12 equal monthly installments from the date of grant of December 15, 2018.